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ORIGINAL ARTICLE
Long-term treatment with a calcineurin inhibi-
tor (CNI) has been shown to cause renal toxic-
ity and chronic renal allograft dysfunction.1,2
Sirolimus (SRL), a new immunosuppressant
without nephrotoxicity has provided a great 
opportunity to improve long-term graft sur-
vival in renal transplantation.3,4 The Rapamune
Maintenance Regimen Study Group recently 
reported that early withdrawal of cyclosporine
from a cyclosporine/SRL/steroid regimen im-
proved renal function and graft survival.5,6
In addition, early tacrolimus withdrawal from 
a regimen with SRL and tacrolimus has also 
been shown to bring about better renal function
and significantly lower diastolic blood pres-
sure.7 Therefore, CNI-free SRL-based maintenance
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therapy might be beneficial for renal transplant 
recipients.
Hyperlipidemia is a matter of serious concern
to patients taking high-dose SRL and steroids,
and so are pulmonary complications, including
interstitial pneumonitis and tuberculosis (TB).8–11
As Renders et al recently demonstrated that low-
dose SRL in combination with mycophenolate
mofetil (MMF) improves kidney graft function
late after renal transplantation, combined SRL and
MMF therapy might confer the benefit of CNI
elimination and avoid the troublesome side effects
of high-dose SRL.12 Early clinical studies have doc-
umented that MMF, as compared with azathio-
prine, decreased the incidence of acute rejection in
cyclosporine-based regimens.13 Moreover, pharma-
cokinetic studies suggested a 12-hour area under
the concentration curve (AUC) of 30–60 mg/L·
hour or a trough mycophenolic acid (MPA) con-
centration of 1–3.5 mg/L for reduction of acute
rejection episodes in the early post-transplant
period.14 Continued MMF therapy for 12 months
or longer was shown to preserve renal allograft
function from progressive decline.15
While Flechner et al demonstrated excellent
results in de novo renal transplants using SRL and
MMF in combination with anti-CD25 antibody
induction and steroids, it appeared that elimina-
tion of CNIs and conversion to maintenance SRL
and MMF therapy could provide adequate im-
munosuppression.16 However, the pharmacoki-
netic interaction between MMF and SRL has not
been well characterized, nor has the dosage of
combined SRL and MMF therapy in Asians. We
thus conducted an investigator-initiated pilot study
to determine any advantage and/or disadvantage
of CNI elimination and conversion to combined
SRL/MMF/steroid therapy in stable Taiwanese
renal transplant recipients. Therapeutic drug mon-
itoring of SRL and MMF was therefore performed.
Materials and Methods
A single-arm prospective study was undertaken to
determine the advantages and disadvantages of late
elimination of CNI and conversion to combined
SRL and MMF therapy in stable Taiwanese renal
transplant recipients. The study protocol was ap-
proved by the National Taiwan University Hospital
Research Ethics Committee and patients gave their
consent to receive the CNI-free immunosuppres-
sive therapy. Adult renal transplant recipients 
on de novo cyclosporine- (Sandimmune Neoral,
Novartis, Basel, Switzerland) or tacrolimus-based
(Prograf, Fujisawa, London, UK) immunosuppres-
sive therapy for at least 6 months were recruited.
Recipients were excluded if they had recent acute
rejection or deterioration of renal function (>30%)
within 12 weeks prior to enrolment. The screening
procedures included complete blood counts, bio-
chemistry tests, abdominal and renal sonography,
chest X-ray, urinalysis and fasting blood sugar.
Patients with steroid withdrawal, obstructive uropa-
thy, multiple organ transplants, malignancy, hepa-
titis B, hepatitis C or active infection were excluded.
The primary immunosuppressive regimens
before CNI withdrawal were a CNI combined with
either SRL (Rapamune, Wyeth-Ayerst, Philadelphia,
USA) or MMF (Cellcept, Roche, Humacao, Puerto
Rico). CNI elimination was accomplished through
a 3-month transitional period of CNI minimiza-
tion in combination with SRL/MMF/steroids be-
fore cyclosporine or tacrolimus was completely
withdrawn. For those on primary CNI/MMF/
steroids therapy, 2 mg of SRL was added to the im-
munosuppression regimen with 50% dose re-
duction of the primary CNI and MMF during the
first month of the 3-month transitional period.
And, during the second month of the transitional
period, CNI doses were further reduced to one
fourth of the primary doses, and the dose of SRL
adjusted to hit the target trough level, 8 nm/mL
(monoclonal immunoassay). Then, the doses of
CNI were further reduced, and MMF adjusted to
reach a minimal daily dose of 1.5 g/day or white
blood cell (WBC) counts around 4000/mm3 dur-
ing the third month of the transitional period. As
to patients on primary CNI/SRL/steroids therapy,
CNI doses were gradually reduced and eventually
eliminated, and MMF introduced during the
transitional period. After CNI withdrawal, the SRL
whole blood trough levels were checked monthly,
and the doses were adjusted to maintain trough
levels between 8 and 12 ng/mL. The target MMF
dose was 2 g/day unless there was a WBC < 4000/
mm3 or intolerance to MMF. For patients with
intolerance, the MMF dose was reduced. Neither
antacids nor H2-blockers were administered to
relieve gastrointestinal side effects. A pharmaco-
kinetic monitoring of MMF was conducted at least
6 months after CNI withdrawal when a steady state
of immunosuppression was achieved. The enzyme-
multiplied immunoassay technique was employed
and validated by the Proficiency Testing Program.17
A three-sample method (C0, C0.5 and C2) by Shaw
et al18 was used to calculate the abbreviated AUC
of MPA.18 The abbreviated AUC0–12h of MPA was
calculated using the regression equation:
7.75 + 6.49C0 + 0.76C0.5 + 2.43C2 (r2 = 0.862)
The primary endpoints of this study were inci-
dence of acute rejection and renal function after
CNI elimination. The secondary endpoints were
graft and patient survival, side effects and infec-
tious complications. Patients with significant de-
terioration of renal function (> 30%) underwent
graft renal biopsy, and biopsy-proven acute re-
jection was treated with corticosteroids. The glo-
merular filtration rate (GFR) immediately before 
and after CNI withdrawal was estimated by the
Cockcroft–Gault formula, with a correction fac-
tor of 0.85 for women and compared by paired
t test. History taking, physical examination, com-
plete blood count, platelet counts, urinalysis and
fasting blood chemistries, including blood urea
nitrogen, serum creatinine, glucose, serum aspar-
tate aminotransferase and alanine aminotrans-
ferase, triglycerides, cholesterol, alkaline phosphate
and lactate dehydrogenase were regularly checked
for identification of side effects. If hypertriglyc-
eridemia (>200 mg/dL) and hypercholesterolemia
(> 240 mg/dL) were sustained for more than 3
months, treatment with fibrates and statins was
initiated, respectively. The doses of fibrate and
statin therapies were minimized if the follow-up
lipid profiles normalized. Patients resumed their
original CNIs when SRL or MMF dose was signif-
icantly reduced because of side effects. Infectious
complications were treated with empirical and
then pathogen-specific antimicrobial therapy. 
Immunosuppressive therapy was not reduced
during infectious episodes unless the episodes
were life threatening.
Results
Seventeen male and 13 female patients were en-
rolled to receive the combined SRL/MMF/steroid
maintenance immunosuppressive therapy between
June and August 2004. Seven of the 30 patients
had been taking tacrolimus-based immunosup-
pressive therapy and the others cyclosporine-based
regimens. The patients ranged in age from 19 to
67 years (43.5 ± 12.4 years). They were placed on
the study immunosuppressive regimen at 9–72
months (31.7±18.6 months) post-transplantation.
The average serum creatinine level before elimina-
tion of CNIs was 1.48 ± 0.42 mg/dL (1.0–2.8 mg/
dL), and the average GFR 49.45±19.40 mL/minute
(24.6–116.4 mL/min). During the transition pe-
riod and the 12-month study period, two patients
resumed cyclosporine because of elevation of liver
enzymes and two resumed tacrolimus, one be-
cause of IgA nephropathy and patient’s request
(Patient 10) at 10 months and the other because
of ventral hernia repair at 8 months. One patient
with leukopenia stopped receiving MMF 1 month
after CNI withdrawal but remained CNI-free.
The graft and patient survival rates were both
100% at 1 year, although one of the 30 patients
(3.33%, 1/30) had biopsy-proven acute rejection
(Banff 97 IA). The specimen of renal biopsy
showed Banff IA acute cellular rejection, and 
the patient received steroid pulse therapy in ad-
dition to the maintenance combined SRL/MMF/
steroid therapy. The rejection episode resolved
smoothly and the patient was maintained on the
study regimen without further decline in renal
function. On intent-to-treat analysis, the average
serum creatinine levels were 1.39±0.39 and 1.41±
0.60 mg/dL at 6 and 12 months, respectively, and
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the average GFRs were 52.94 ± 18.40 and 54.02 ±
20.34 mL/minute at 6 and 12 months, respectively
(Figure 1A). One patient (Patient 10) among the
30 patients had significant deterioration in renal
function because of biopsy-proven IgA nephropa-
thy. The GFR from 4 to 12 months after with-
drawal of CNIs was significantly higher than the
baseline GFR on the paired t test. However, we
could not identify any subgroup (including patient
age, gender, graft age, primary CNI and baseline
GFR upon CNI elimination) of patients who
would be predicted to benefit from combined
SRL and MMF therapy. Details of patient demo-
graphics and outcomes are summarized in the
Table. As for on-therapy analysis, the average
serum creatinine levels of patients on CNI-free
therapy were 1.4 ± 0.41 and 1.29±0.35mg/dL at
6 and 12 months, respectively, and the average 
on-therapy GFRs were 51.09 ± 16.74 and 54.82 ±
17.86 mL/minute at 6 and 12 months, respectively
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Figure 1. Average serum creatinine levels (sCre) and estimated glomerular filtration rates (GFR) of renal transplant 
patients before and after withdrawal of calcineurin inhibitors (CNI) and conversion to combined sirolimus and mycophe-
nolate mofetil therapy in (A) intent-to-treat analysis and (B) on-therapy analysis compared with baseline renal function
just before CNI withdrawal. *p < 0.05; †p < 0.01; ‡p < 0.001; §p < 0.0001.
Table. Demographics and outcomes of the 30 patients enrolled for the combined SRL and MMF therapy after
withdrawal of CNIs
Patient demographics and outcomes* Mean Range
Patient age (yr) 43.5 ± 12.4 19–67
Graft age (months post-transplant) 31.7 ± 18.6 9–72
Gender (male/female) 17/13 –
Primary CNI (cyclosporine/tacrolimus) 23/7 –
Baseline sCre (mg/dL) 1.48 ± 0.42 1.0–2.8
Baseline estimated GFR (mL/min) 49.45 ± 19.40 24.6–116.4
sCre at 12 mo (mg/dL) 1.41 ± 0.60 0.9–4.0
Estimated GFR at 12 mo (mL/min) 54.02 ± 20.34 17.3–98.5
Acute rejection at 12 mo 3.33% (1/30) –
Graft survival at 12 mo 100% (30/30) –
Leukopenia (< 4000/mm3) 3.33% (1/30) –
Anemia (Hb < 10 g/dL) 3.33% (1/30) –
Hyperlipidemia (> 200 mg/dL) 33.33% (10/30) –
Hypercholesterolemia (> 240 mg/dL) 30.00% (9/30) –
Major infections 16.67% (5/30) –
*Results of intent-to-treat analysis are shown. SRL = sirolimus; MMF = mycophenolate mofetil; CNI = calcineurin inhibitor; sCre =
serum creatinine; GFR = glomerular filtration rate; Hb = hemoglobin.
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(Figure 1B). The on-therapy GFR from 4 to 
12 months was also significantly higher than the
corresponding baseline GFR on the paired t test.
After CNI withdrawal, the average doses of SRL
were 2.38 ± 0.81 and 2.25 ± 0.89 mg/day at 6 and
12 months, respectively, and the trough blood
levels were 7.87 ± 3.84 and 7.38 ± 3.74 ng/mL at
6 and 12 months, respectively. Details of SRL doses
and trough blood levels are shown in Figure 2.
The average MMF doses were 1.50 ± 0.44 and
1.45 ± 0.56 g/day at 6 and 12 months, respectively
(Figure 2). Eighteen of the 25 patients who re-
mained on the combined SRL/MMF/steroid regi-
men agreed to undergo the pharmacokinetic study
of MPA. Their albumin levels ranged from 3.9 to
5.0 g/dL. The average MPA C0 was 3.21±2.55 mg/L,
average C0.5 21.81 ± 13.67 mg/L and average C2
8.10±6.28mg/L. The abbreviated AUC0-12h of MPA
ranged from 26.0 to 150.3 mg/L·hour, and the
average AUC0–12h of MPA was 64.86±36.62mg/L·
hour at an average MMF dose of 1.56±0.45g/day.
Although SRL and MMF both have the side effect
of bone marrow suppression, the platelet and
WBC counts of patients with CNI elimination
were maintained above 4000/mm3 except in the
case of one patient who stopped MMF therapy
due to marked leukopenia. The average on-therapy
platelet and WBC counts are shown in Figure 3.
Besides, there was one patient with persistent
symptomatic anemia (hemoglobin < 10 g/dL).
The average hemoglobin level at 6 months was
12.7±1.6g/dL (range, 9.6–16.3g/dL). As for hyper-
lipidemia, 10 patients (33.3%, 10/30) received fi-
brates and nine patients (30.0%, 9/30) were given
statins to normalize their lipid profiles. The average
on-therapy triglyceride levels were 154.3 ± 81.9
and 152.2 ± 72.5 mg/dL at 6 and 12 months, re-
spectively. The average on-therapy cholesterol lev-
els were 247.4 ± 39.9 at 6 months and 226.7 ±
35.4 mg/dL at 12 months (Figure 4).
During the study period, three female patients
were hospitalized because of urinary tract infec-
tion and sepsis. The pathogens were found to be
Escherichia coli in two patients and Enterococcus
species in the other. Based on sensitivity tests, an-
tibiotics were given and the infections were con-
trolled. Another two patients, Patient 3 and
Patient 22, had severe productive cough and weight
loss at 4 and 3 months, respectively, after CNI
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Figure 2. Average mycophenolate mofetil (MMF) and
sirolimus (SRL) daily doses and trough SRL levels for renal
transplant recipients on combined SRL and MMF therapy.
CNI = calcineurin inhibitors.
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Figure 3. Average platelet (PLT) and white blood cell
(WBC) counts for renal transplant recipients on combined
sirolimus and mycophenolate mofetil therapy. CNI = cal-
cineurin inhibitors.
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Figure 4. Average triglyceride (TG) and cholesterol (CHO)
levels for renal transplant recipients on combined siroli-
mus and mycophenolate mofetil therapy. CNI = calcineurin 
inhibitors.
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withdrawal. Both patients had chest films showing
interstitial infiltration and cavitations over bilat-
eral upper lung fields. Representative chest X-ray
films of Patient 3 before and after CNI withdrawal
are shown in Figure 5. Expectorated sputum cul-
tures and sensitivity tests in the two patients both
yielded Mycobacterium tuberculosis with suscepti-
bility to isoniazid, rifampin, ethambutol and
streptomycin. Both patients primarily received a
four-drug combination which included isoni-
azid, rifampin, ethambutol and pyrazinamide for
the initial 2 months followed by three-drug therapy
for 7 months with pyrazinamide discontinued.
However, isoniazid was replaced by moxifloxacin
in Patient 3 because of elevated liver enzymes.
Both patients completed the 9-month anti-TB ther-
apy and recovered very well. No evidence of re-
lapse was detected after the anti-TB therapy was
stopped. To differentiate the causes of TB infec-
tion in our patients, we reviewed all the screening
chest films obtained before our study. Among
the 30 patients recruited, four, including the two
patients with pulmonary TB, had had fibro-
calcified change in the upper lung fields on the
screening chest films, which was suggestive of in-
active pulmonary TB before our study. The other
26 patients whose chest films showed no evidence
of previous TB lesions did not have TB during
the study period. In this study, the incidence of
pulmonary TB was found to be significantly higher
(p=0.0138, Fisher’s exact test) among patients with
inactive TB lesions (50%, 2/4) than among those
without such lesions (0%, 0/26).
Discussion
The findings from this pilot study in Taiwan are
consistent with those from previous reports in the
US and Europe, which showed beneficial effects
of CNI withdrawal even late after renal transplan-
tation.19,20 The risk of acute rejection was low
(3.33%) and renal function improved significantly
from 4 months after CNI withdrawal to the end
of the 12-month study period. Our results suggest
that CNIs at their maintenance doses are nephro-
toxic to renal transplants. Withdrawal of CNIs
and conversion to a CNI-free regimen amelio-
rated the detrimental effects of CNIs and hope-
fully can promote long-term graft survival in stable
renal transplant patients. However, we introduced
MMF to our CNI-free regimen in order to lessen
A B
Figure 5. Representative chest films of Patient 3 (A) before and (B) 4 months after calcineurin inhibitor withdrawal and
conversion to combined sirolimus and mycophenolate mofetil therapy.
the dyslipidemic side effect of high-dose SRL. The
mean SRL dose (2.25 ± 0.89 mg/day) and whole
blood level (7.38 ± 3.74 ng/mL, measured by im-
munoassay) at 12 months were lower than those
reported by Watson et al21 (3.5 mg/day and 8.8 ng/
mL by high-performance liquid chromatography)
using SRL and steroids only. Furthermore, to nor-
malize the serum total cholesterol levels, statins
were only needed in 30.0% of our patients (9/30),
which was lower than the incidences (43.9–78.9%)
reported in the literature.5,21,22 Our results showed
that conversion to a combined SRL and MMF reg-
imen provides good renal function with minimal
dyslipidemia.
While combined therapy of SRL and MMF less-
ened dyslipidemia, bone marrow suppression,
which is a common side effect of SRL and MMF
was a cause for considerable concern. Interestingly,
the average WBC counts in our study were all above
6000/mm3 with only one patient having to stop
MMF because of leukopenia. Also, the platelet
counts of our patients were above the lower normal
limit. Combined SRL and MMF therapy seemed
to produce only a limited effect on the bone
marrow. However, two of our patients suffered
from pulmonary TB at 3 and 4 months after com-
bined SRL and MMF therapy. The active TB infec-
tions in the two patients seemed to be caused by
reactivation of old pulmonary foci, which were ev-
ident on the screening chest films. Fortunately,
the sputum cultures and sensitivity tests in the
two patients did not yield multidrug-resistant 
M. tuberculosis, which is now an increasingly serious
health problem in Taiwan.23 Even though there is a
noticeable drug interaction between SRL and ri-
fampin, we were still able to apply the combined
SRL and MMF therapy to patients on anti-TB
treatment by increasing the daily dose of SRL and
maintaining the same target trough level.
Combined SRL and MMF therapy might in-
crease the risk of TB infection in long-term im-
munosuppressed transplant recipients, as SRL and
MMF both suppress T-cell proliferation, which is
important for immunity against mycobacterium.24
Therapeutic drug monitoring of SRL and MMF
should be employed because it is crucial for the
success of this CNI-free regimen. We found that
MMF at an average daily dose of 1.56 ± 0.45 g/day,
when combined with SRL, could achieve a sat-
isfactory MPA AUC0–12h of 64.86 ± 36.62 mg/L·
hour, which was higher than the average AUC0–12h
(48.70±19.01mg/L·hour, n=5) in our other study
which employed similar doses of MMF (1.60 ±
0.55 g/day) in combination with cyclosporine
(FDCC [Fixed Dose vs. Concentration Controlled
study], data exposure approved by Roche). Our
findings support Render’s suggestion that there
might be a pharmacokinetic interaction between
SRL and MMF.12 While adequate MPA exposure
significantly decreased the risk of acute rejection,
dosage of SRL should be reduced to avoid overt
T-cell suppression, especially in Asian countries
where TB is prevalent.
Renal transplant recipients should be screened
for latent TB infection before receiving potent im-
munosuppressive agents such as MMF and SRL.
Reactivation has been noted to be the most com-
mon form of TB in renal transplant recipients, and
Ataserver et al showed that MMF was associated
with the development of TB at a younger age and
at a higher frequency when compared with con-
ventional therapy.25,26 Additionally, SRL has been
found to be frequently associated with pulmonary
complications, including TB and pneumonitis.9–11
While the tuberculin skin test is not relevant to
screening latent TB infection in Taiwan, we found
that chest films provide valuable information. In
this study, we showed that patients with apical fi-
brocalcified lesions on chest films carried a very
high risk of TB reactivation (50%, 2/4) when re-
ceiving combined MMF and SRL therapy. On the
contrary, there was little risk of primary pulmonary
TB (0%, 0/26) for patients without latent infection.
To receive potent immunosuppressive therapy tar-
geting T-cell proliferation, such as SRL and MMF,
transplant patients should be screened for latent
TB infection. Isoniazid chemoprophylaxis might
be necessary in countries where TB is endemic.27
In conclusion, we demonstrated that with-
drawal of CNIs and conversion to combined SRL
and MMF therapy improved renal function in
stable renal transplant patients, although there was
M.K. Tsai, et al
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a risk of TB reactivation for those with latent TB
infection.
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